Genfit logo
Genfit
GNFT | NASDAQ
Chart Builder DCF Calculator
$8.95
+$0.35 (+4.07%)
At close: Nov 10, 2025, 3:55 PM ET

Genfit Company Profile

Company profile explained

Company Profile

Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developing its NIS4 technology, designed to aid in the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company's pipeline further encompasses GNS561, which is in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation as a potential therapy for acute-on-chronic liver failure. Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Additionally, it collaborates with Genoscience Pharma to jointly develop and market the investigational treatment GNS561 for CCA. Founded in 1999, Genfit S.A. is headquartered in Loos, France.

Key Executives

Name Position
Pascal Prigent Chief Executive Officer
Pascal Caisey Chief Operating Officer
Thomas Baetz Chief Financial Officer
Bart Staels Co-Founder & Chairman of the Scientific Advisory Board
Emilie Desodt Executive Vice President of Human Resources
Jean-Christophe Marcoux Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
Jean-Francois Mouney Co-Founder & Chairman of the Board
Laurent Lannoo Corporate Secretary & Director of Legal Affairs
Sakina Sayah-Jeanne Chief Scientific Officer
Stefanie Magner Chief Compliance Officer & Executive Vice President of International Legal Affairs

Latest SEC Filings

Date Type Title
Nov 20, 2025 15F-12B Filing
Nov 14, 2025 S-8 POS Filing
Nov 14, 2025 RW Filing
Nov 10, 2025 6-K Filing
Nov 10, 2025 6-K Filing
Nov 10, 2025 25 Filing
Oct 30, 2025 6-K Filing
Oct 28, 2025 6-K Filing
View All SEC Filings ➞
Genfit
Genfit logo
Country France
IPO Date Mar 27, 2019
Industry Biotechnology
Sector Healthcare
Employees 180
CEO M. Pascal Prigent

Contact Details

Parc EurasantE Loos 59120 France

Stock Details

Ticker Symbol GNFT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001757064
CUSIP Number 372279109
ISIN Number US3722791098
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.